Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)

Abstract

Methylphenidate (MPH), a stimulant drug with dopamine and noradrenaline reuptake inhibition properties, is mainly prescribed in attention deficit hyperactivity disorder, is increasingly used by the general population, intending to enhance their cognitive function. In this literature review, we aim to answer whether this is effective. We present a novel way to determine the extent to which MPH enhances cognitive performance in a certain domain. Namely, we quantify this by a percentage that reflects the number of studies showing performance enhancing effects of MPH. To evaluate whether the dose-response relationship follows an inverted-U-shaped curve, MPH effects on cognition are also quantified for low, medium and high doses, respectively. The studies reviewed here show that single doses of MPH improve cognitive performance in the healthy population in the domains of working memory (65% of included studies) and speed of processing (48%), and to a lesser extent may also improve verbal learning and memory (31%), attention and vigilance (29%) and reasoning and problem solving (18%), but does not have an effect on visual learning and memory. MPH effects are dose-dependent and the dose-response relationship differs between cognitive domains. MPH use is associated with side effects and other adverse consequences, such as potential abuse. Future studies should focus on MPH specifically to adequately asses its benefits in relation to the risks specific to this drug.
Original languageEnglish
Pages (from-to)961-977
Number of pages17
JournalInternational Journal of Neuropsychopharmacology
Volume17
Issue number6
Early online date15 Jan 2014
DOIs
Publication statusPublished - Jun 2014

Keywords

  • Cognition
  • Dopamine
  • Memory
  • Methylphenidate
  • EVENT-RELATED POTENTIALS
  • NORMAL ADULT HUMANS
  • ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
  • IMMEDIATE-RELEASE METHYLPHENIDATE
  • SPATIAL WORKING-MEMORY
  • YOUNG-ADULTS
  • D-AMPHETAMINE
  • HUMAN BRAIN
  • ORAL METHYLPHENIDATE
  • RESPONSE-INHIBITION

Cite this

@article{0acd50827b1c48b7ba9301f7436a245f,
title = "Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies",
abstract = "Methylphenidate (MPH), a stimulant drug with dopamine and noradrenaline reuptake inhibition properties, is mainly prescribed in attention deficit hyperactivity disorder, is increasingly used by the general population, intending to enhance their cognitive function. In this literature review, we aim to answer whether this is effective. We present a novel way to determine the extent to which MPH enhances cognitive performance in a certain domain. Namely, we quantify this by a percentage that reflects the number of studies showing performance enhancing effects of MPH. To evaluate whether the dose-response relationship follows an inverted-U-shaped curve, MPH effects on cognition are also quantified for low, medium and high doses, respectively. The studies reviewed here show that single doses of MPH improve cognitive performance in the healthy population in the domains of working memory (65{\%} of included studies) and speed of processing (48{\%}), and to a lesser extent may also improve verbal learning and memory (31{\%}), attention and vigilance (29{\%}) and reasoning and problem solving (18{\%}), but does not have an effect on visual learning and memory. MPH effects are dose-dependent and the dose-response relationship differs between cognitive domains. MPH use is associated with side effects and other adverse consequences, such as potential abuse. Future studies should focus on MPH specifically to adequately asses its benefits in relation to the risks specific to this drug.",
keywords = "Cognition, Dopamine, Memory, Methylphenidate, EVENT-RELATED POTENTIALS, NORMAL ADULT HUMANS, ATTENTION-DEFICIT/HYPERACTIVITY DISORDER, IMMEDIATE-RELEASE METHYLPHENIDATE, SPATIAL WORKING-MEMORY, YOUNG-ADULTS, D-AMPHETAMINE, HUMAN BRAIN, ORAL METHYLPHENIDATE, RESPONSE-INHIBITION",
author = "A.M.W. Linssen and A. Sambeth and E.F.P.M. Vuurman and W.J. Riedel",
year = "2014",
month = "6",
doi = "10.1017/S1461145713001594",
language = "English",
volume = "17",
pages = "961--977",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Oxford University Press",
number = "6",

}

Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. / Linssen, A.M.W.; Sambeth, A.; Vuurman, E.F.P.M.; Riedel, W.J.

In: International Journal of Neuropsychopharmacology, Vol. 17, No. 6, 06.2014, p. 961-977.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies

AU - Linssen, A.M.W.

AU - Sambeth, A.

AU - Vuurman, E.F.P.M.

AU - Riedel, W.J.

PY - 2014/6

Y1 - 2014/6

N2 - Methylphenidate (MPH), a stimulant drug with dopamine and noradrenaline reuptake inhibition properties, is mainly prescribed in attention deficit hyperactivity disorder, is increasingly used by the general population, intending to enhance their cognitive function. In this literature review, we aim to answer whether this is effective. We present a novel way to determine the extent to which MPH enhances cognitive performance in a certain domain. Namely, we quantify this by a percentage that reflects the number of studies showing performance enhancing effects of MPH. To evaluate whether the dose-response relationship follows an inverted-U-shaped curve, MPH effects on cognition are also quantified for low, medium and high doses, respectively. The studies reviewed here show that single doses of MPH improve cognitive performance in the healthy population in the domains of working memory (65% of included studies) and speed of processing (48%), and to a lesser extent may also improve verbal learning and memory (31%), attention and vigilance (29%) and reasoning and problem solving (18%), but does not have an effect on visual learning and memory. MPH effects are dose-dependent and the dose-response relationship differs between cognitive domains. MPH use is associated with side effects and other adverse consequences, such as potential abuse. Future studies should focus on MPH specifically to adequately asses its benefits in relation to the risks specific to this drug.

AB - Methylphenidate (MPH), a stimulant drug with dopamine and noradrenaline reuptake inhibition properties, is mainly prescribed in attention deficit hyperactivity disorder, is increasingly used by the general population, intending to enhance their cognitive function. In this literature review, we aim to answer whether this is effective. We present a novel way to determine the extent to which MPH enhances cognitive performance in a certain domain. Namely, we quantify this by a percentage that reflects the number of studies showing performance enhancing effects of MPH. To evaluate whether the dose-response relationship follows an inverted-U-shaped curve, MPH effects on cognition are also quantified for low, medium and high doses, respectively. The studies reviewed here show that single doses of MPH improve cognitive performance in the healthy population in the domains of working memory (65% of included studies) and speed of processing (48%), and to a lesser extent may also improve verbal learning and memory (31%), attention and vigilance (29%) and reasoning and problem solving (18%), but does not have an effect on visual learning and memory. MPH effects are dose-dependent and the dose-response relationship differs between cognitive domains. MPH use is associated with side effects and other adverse consequences, such as potential abuse. Future studies should focus on MPH specifically to adequately asses its benefits in relation to the risks specific to this drug.

KW - Cognition

KW - Dopamine

KW - Memory

KW - Methylphenidate

KW - EVENT-RELATED POTENTIALS

KW - NORMAL ADULT HUMANS

KW - ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

KW - IMMEDIATE-RELEASE METHYLPHENIDATE

KW - SPATIAL WORKING-MEMORY

KW - YOUNG-ADULTS

KW - D-AMPHETAMINE

KW - HUMAN BRAIN

KW - ORAL METHYLPHENIDATE

KW - RESPONSE-INHIBITION

U2 - 10.1017/S1461145713001594

DO - 10.1017/S1461145713001594

M3 - Article

VL - 17

SP - 961

EP - 977

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 6

ER -